Literature DB >> 11437722

The expression of cyclooxygenase 2 and inducible nitric oxide synthase indicates no active inflammation in vulvar vestibulitis.

N Bohm-Starke1, C Falconer, E Rylander, M Hilliges.   

Abstract

BACKGROUND: Although women with vulvar vestibulitis syndrome have principal symptoms of inflammation such as local erythema and pain in the mucosa around the vaginal introitus, it is not clear if vestibulitis is an inflammatory condition. Cyclooxygenase 2 and inducible nitric oxide synthase are known to be upregulated during inflammation. The aim of the present study was to analyze the expression of these enzymes in the vestibular mucosa in order to evaluate the inflammatory activity in the tissue.
METHODS: Ten women fulfilling Friedrich's criteria of vulvar vestibulitis syndrome and ten control subjects were included in the study. Punch biopsies were obtained from the vestibular mucosa for analysis of cyclooxygenas 2 and inducible nitric oxide synthase, using indirect immunohistochemistry and Western dot-blot analyses.
RESULTS: Both methods used showed low expression of cyclooxygenas 2 and inducible nitric oxide synthase in the vestibular mucosa of all women. There was no difference observed between the groups.
CONCLUSIONS: There is a low expression of the inflammatory markers cyclooxygenas 2 and inducible nitric oxide synthase in the vestibular mucosa of women with vulvar vestibulitis syndrome as well as in healthy control subjects. The results indicate no active inflammation present and imply that topical corticosteroids in the treatment of vulvar vestibulitis are unfounded.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11437722

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  6 in total

1.  Differences in primary compared with secondary vestibulodynia by immunohistochemistry.

Authors:  Catherine M Leclair; Martha F Goetsch; Veselina B Korcheva; Ross Anderson; Dawn Peters; Terry K Morgan
Journal:  Obstet Gynecol       Date:  2011-06       Impact factor: 7.661

2.  Rationale and design of a multicenter randomized clinical trial of extended release gabapentin in provoked vestibulodynia and biological correlates of response.

Authors:  Candace S Brown; David C Foster; Jim Y Wan; Leslie A Rawlinson; Gloria A Bachmann
Journal:  Contemp Clin Trials       Date:  2013-06-29       Impact factor: 2.226

3.  Vestibular Mast Cell Density in Vulvodynia: A Case-Controlled Study.

Authors:  Dimitrios Papoutsis; Hope K Haefner; Christopher P Crum; Anthony W Opipari; Barbara D Reed
Journal:  J Low Genit Tract Dis       Date:  2016-07       Impact factor: 1.925

4.  Vulvar vestibulitis syndrome.

Authors:  Carolyn Gardella
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.663

Review 5.  Recent advances in understanding provoked vestibulodynia.

Authors:  Ahinoam Lev-Sagie; Steven S Witkin
Journal:  F1000Res       Date:  2016-10-26

6.  New topical treatment of vulvodynia based on the pathogenetic role of cross talk between nociceptors, immunocompetent cells, and epithelial cells.

Authors:  J M Keppel Hesselink; D J Kopsky; N Sajben
Journal:  J Pain Res       Date:  2016-10-03       Impact factor: 3.133

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.